Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
ELCC 2018
The 8th European Lung Cancer Conference
Access to all presentations that took place at ELCC 2018 in Geneva, Switzerland
Presentation Date(s):- Apr 11 - 14, 2018
- Total Presentations: 407
-
+
Opening and welcome
- Type: Opening and welcome
- Presentations: 4
- Moderators:L. Paz-Ares
- Coordinates: 4/11/2018, 13:30 - 13:45, Room B
-
+
Welcome to the Congress
13:30 - 13:35 | Presenter: M. Perol
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Introduction to ESMO
13:35 - 13:40 | Presenter: S. Peters
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Introduction to IASLC
13:40 - 13:45 | Presenter: G. Scagliotti
- Abstract
No abstract available for this presentation
-
+
2018 HHH Award Winner Introduction
13:45 - 13:45 | Presenter: S. Peters
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Immunotherapy and next-generation TKIs: From second to frontline treatment
- Type: Poster Discussion session
- Presentations: 18
- Moderators:P. Garrido Lopez
- Coordinates: 4/12/2018, 07:45 - 09:00, Room A
-
+
138PD_PR - Patient-reported outcomes (PROs) in ALEX: A phase III study of alectinib (ALEC) vs crizotinib (CRIZ) in non-small-cell lung cancer (NSCLC)
10:54 - 10:54 | Presenter: M. Perol
- Abstract
Loading...
-
+
New approaches in rare thoracic tumors
- Type: Proffered Paper session
- Presentations: 6
- Moderators:M. Perol
- Coordinates: 4/13/2018, 11:00 - 12:30, Room A
-
+
135O - A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer
11:00 - 11:15 | Presenter: B. Besse
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Invited Discussant 135O
11:15 - 11:25 | Presenter: M. Perol
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
112O - Primary result of an investigator-initiated phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study (NCCH1505)
11:25 - 11:40 | Presenter: T. Seto
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
213O - Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma (MPM): Phase II biomarker data from the LUME Meso study
11:40 - 11:55 | Presenter: N. Pavlakis
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
214O - Multiplexed proteomics biomarkers for malignant pleural mesothelioma detection in blood
11:55 - 12:10 | Presenter: F. Cerciello
- Abstract
Loading... -
+
Invited Discussant 112O, 213O and 214O
12:10 - 12:30 | Presenter: N. Girard
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
ESMO-IASLC Best Abstracts
- Type: Best Abstract session
- Presentations: 7
- Moderators:M. Perol
- Coordinates: 4/13/2018, 16:45 - 18:30, Room B
-
+
91O - Adjuvant chemotherapy candidates in stage I lung adenocarcinomas following complete lobectomy: What does an analysis based on recurrence risk stratification tell us?
16:45 - 17:00 | Presenter: J. Qian
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
109O - Health-related quality of life (QoL) after prophylactic cranial irradiation (PCI) vs no PCI for stage III NSCLC patients: Results from the NVALT-11/DLCRG-02 study
17:00 - 17:15 | Presenter: W. Witlox
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
233O - Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes
17:15 - 17:30 | Author(s): R. Hui
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Invited Discussant 91O, 109O and 233O
17:30 - 17:45 | Presenter: N. Reguart
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
128O - Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
17:45 - 18:00 | Presenter: D. Planchard
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
129O - EGFR-TKIs plus local therapy demonstrated survival benefit than TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases
18:00 - 18:15 | Presenter: T. Jiang
- Abstract
Loading... -
+
Invited Discussant 128O and 129O
18:15 - 18:30 | Presenter: T. Mitsudomi
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Closing remarks
- Type: Closing remarks
- Presentations: 1
